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First person – Katie Lloyd and Stamatia Papoutsopoulou
First Person is a series of interviewswith the first authors of a selection of
papers published in Disease Models & Mechanisms, helping early-
career researchers promote themselves alongside their papers. Katie
Lloyd and Stamatia Papoutsopoulou are co-first authors on ‘Using
systems medicine to identify a therapeutic agent with potential for
repurposing in inflammatory bowel disease’, published in DMM. Katie
conducted the research described in this article while a postdoctoral
research associate in Prof. Chris Probert’s lab at the University of
Liverpool, Liverpool, UK. She is now a lecturer in pharmacology at
the University of Chester, Chester, UK. Her research focuses on
personalising medicine by combining innovative experimental
approaches to identify biomarkers of inflammatory disease, drug
response and mechanisms of drug resistance, which consider
complex factors such as inter-patient variability and co-morbidities.
Stamatia conducted the research described in this article while a
postdoctoral research associate in Werner Muller’s lab at the University
of Manchester, Manchester, UK. She is currently a postdoctoral
research associate in the lab of Mark Pritchard at the University of
Liverpool, Liverpool, UK, investigating the regulation of transcriptional
responses during inflammation and the impact of environmental factors
on them, and has just accepted the position of assistant professor at the
University of Thessaly, Greece.
How would you explain the main findings of your paper
to non-scientific family and friends?
KL: We wanted to identify drugs that are already safe and well
tolerated for one condition, which might also be used to treat
inflammatory bowel disease (IBD). We used computerized analysis
of the chemical structure of the drugs to predict whether they might
work in IBD. For the most likely candidate drugs, we confirmed
their effects using laboratory tests. One of the most exciting aspects
of the study was the use of ‘mini-gut’ cultures grown in the
laboratory from patients’ tissue samples to test the drugs.
SP: IBD is a very unpredictable medical condition with complex
aggravating factors, often of unknown cause. The aim of this study
was the identification and initial validation of drugs that can be
further tested for IBD patient treatment. For this purpose,
computational methodologies and scientific experiments were
performed, mainly using cells isolated and cultured in the lab.
Our results showed that the antibiotic clarithromycin can inhibit one
of the major inflammatory pathways in the immune system and has
the potential to be tested and used for further investigation.
What are the potential implications of these results for your
field of research?
KL: The availability of new drugs and biological products often
means new treatment options for patients. A deep understanding of
the science used to create new products, testing and manufacturing
procedures, and the disease/conditions that are being treated is
constantly needed to bring new therapies to market. However,
discovering a completely new compound is a very expensive and
time-consuming process. The repurposing of already existing drugs
has a huge potential to deliver new treatments to patients with
incurable diseases such as IBD, quickly and cheaply. Previously
developed drugs have a history of use in humans with a known
safety profile and side effects and, therefore, can reduce preclinical
testing and early-stage clinical trials.
SP: The drug discovery methodology we used identified the
antibiotic clarithromycin as the highest-ranked drug against the
transcription factor NF-κB pathway, and we further showed that it
can inhibit its nuclear translocation and therefore its transcriptional
activity. Clarithromycin has been an approved antibiotic for more
than 20 years, and there are other new-generation antibiotics in the
macrolide family. Therefore, there is a high potential for testing
those drugs for their anti-inflammatory function in IBD and,
possibly, in a cell-specific way, e.g. targeting cells of the immune
system that are major players in the pathogenesis of the disease.
What are the main advantages and drawbacks of the model
system you have used as it relates to the disease you are
investigating?
KL: IBD is an incurable, life-long disease that is typically diagnosed
in patients between the ages of 15 and 35. Due to its chronic nature,
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relapse is extremely common. Many patients develop resistance to
drug treatments, with a significant proportion of patients requiring
surgery at some point in their lifetime, so demand for new treatments
is extremely high. Repurposing approved drugs would increase the
potential for new therapies, particularly for non-responders who may
potentially avoid surgery. However, these treatments still aim to treat
inflammation that triggers symptoms as the cause of IBD is still
largely unknown. Further research is required for preventative
treatments in those who are at high risk of developing IBD, before
the relapse/remission cycle of inflammation begins.
SP: The use of cells harvested from patients to use in live-cell
experiments in the laboratory can be extremely helpful in working
with specific pathways, answering specific questions and avoiding
interference from external factors that can affect the outcome. The
methods we have used make our experiments more relevant than
ever before. Nevertheless, inflammatory diseases are multifactorial
highly complex; eventually they have to be studied in patients as
well as laboratory models.
What has surprised you the most while conducting your
research?
KL: Even after studying many drug compounds through my
degrees and research career, I was surprised that a number of
heavily researched and commonly used drugs were predicted to
affect IBD by our mathematical modelling. As the NF-κB pathway
is known to be activated during chronic inflammation in IBD
patients, I was expecting that anti-inflammatory drugs would be
predicted by our model. We did find a number of anti-
inflammatories, as expected, but it was much more exciting that
drugs such as clarithromycin, a common antibiotic, and digoxin, a
drug used to control heart rate, were also predicted to affect these
debilitating conditions!
SP: Performing experiments in different cell types, while trying to test
a hypothesis can be tedious and disappointing. In this study, I found it
amazing how consistently clarithromycin could consistently inhibit
the specific NF-κB pathway in macrophages under different
experimental conditions in vitro. That included a variety of triggers
to activate NF-κB signalling, different cell types and different
techniques to measure NF-κB activation. These results were hugely
consistent and continuously supported our original hypothesis.
“Over the next 10 years, UK academics
and universities are going to be
challenged to develop new approaches
that will enable our research to flourish.”
Describe what you think is the most significant challenge
impacting your research at this time and how will this be
addressed over the next 10 years?
KL: This project was funded by an EC FP7 grant awarded to a UK
University. The UK’s decision to leave the EU hasmeant that a follow-
up study could not be funded through the same route and has coincided
with several of the key researchers in our collaboration leaving UK
universities. This has combined with the COVID-19 pandemic, to
make research funding particularly difficult to obtain. Over the next
10 years, UK academics and universities are going to be challenged to
develop new approaches that will enable our research to flourish.
SP: The IBDs are a chronic inflammatory condition that involves
functional dysregulation of various cell types, including the immune
system and the intestinal epithelium. The pathogenesis of IBD is
influenced by each individual’s immune system, their microbiome,
environmental factors and genetic predisposition. This has been and
will be the major challenge in delineating how these factors can
influence the disease phenotype, behaviour and response to therapy.
Cell-specific experimental approaches, such as sequencing, on large
human cohorts will help to increase our understanding of the
pathogenesis of the disease and promote personalised medicine.
What changes do you think could improve the professional
lives of early-career scientists?
KL: A greater availability of funding that does not require a
permanent academic position for applicationwould allowmore early-
career researchers to gain experience with applying for and securing
external grants to further their own independent research ideas.
SP: Early-career scientists will gain experience by being actively
involved in various aspects of a scientific project, such as cost and
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Confocal imaging of budding small intestinal organoids showing
fluorescently labelled DNA for nuclear visualisation.
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expenses management, public engagement and interactions with
stakeholders.
What’s next for you?
KL: I have recently accepted a permanent academic position with
the University of Chester, with aims to continue my research in
gastrointestinal inflammation by developing my own research group
at Chester Medical School and collaborations with a network of
experts that I have obtained throughout my research career.
SP: I have recently accepted a permanent academic position at the
University of Thessaly in Greece, where I would like to continue my
research in the field of the NF-κB pathway and inflammation.
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